Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure

被引:38
|
作者
Perianayagam, MC [1 ]
Murray, SL [1 ]
Balakrishnan, VS [1 ]
Guo, DQ [1 ]
King, AJ [1 ]
Pereira, BJG [1 ]
Jaber, BL [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Nephrol, Tupper Res Inst, Dept Med, Boston, MA 02111 USA
来源
关键词
D O I
10.1067/mlc.2000.109318
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Apoptosis, or programmed cell death, is an active form of cell death that is initiated by a number of stimuli and is intricately regulated, Apoptosis in both excessive and reduced amounts has pathophysiologic implications. Accelerated programmed cell death has been observed in leukocytes among patients with chronic renal failure (CRF). This has been ascribed in part to the retention of uremic toxins. The Fas/Fas ligand (FasL) system is a key regulatory apoptotic pathway, Membrane-bound Fas is a cell-surface receptor that transduces apoptosis after interaction with membrane-bound or soluble FasL (sFasL). By contrast, soluble Fas (sFas) binds sFasL and inhibits its activity. In an attempt to examine the balance between these soluble factors in uremia, we measured soluble sFas and sFasL levels in the serum of healthy control subjects and patients with various degrees of CRF and examined the distribution of the various molecular mass fractions of these proteins in uremic serum. In brief, serum was obtained from 15 healthy volunteers, 17 patients with CRF, 11 patients undergoing maintenance hemodialysis (HD), and 7 patients undergoing peritoneal dialysis (PD). Serum sFas and sFasL were measured by enzyme-linked immunosorbent assay, and their molecular distribution was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot. Compared with results in healthy control subjects, sFas levels were significantly higher in patients with CRF and in patients undergoing dialysis. There was a significant inverse correlation between sFas levels and creatinine clearance. Serum sFasL levels were not different among the four groups. However, the sFas-to-sFasL ratio was significantly lower in healthy control subjects as compared with patients with CRF and patients undergoing dialysis. Immunoblots and densitometric analyses of sFas and sFasL depicted a known 48-kd sFas, a known 27-kd sFasL, and a 60-kd sFas-sFasL protein aggregate signal. In conclusion, serum sFas levels are increased in patients with various degrees of CRF and may bind circulating sFasL, thereby minimizing mediation of cellular apoptosis.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [31] CD95 and Fas ligand expression and apoptosis in rheumatoid arthritis.
    Cantwell, MJ
    Hua, T
    Zvaifler, NJ
    Kipps, TJ
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 287 - 287
  • [32] Soluble Fas (CD95/Apo-1), soluble Fas ligand, and activated caspase 3 in the cerebrospinal fluid of infants with posthemorrhagic and nonhemorrhagic hydrocephalus
    Felderhoff-Mueser, U
    Bührer, C
    Groneck, P
    Obladen, M
    Bartmann, P
    Heep, A
    PEDIATRIC RESEARCH, 2003, 54 (05) : 659 - 664
  • [33] Fas (CD95/Apo-1)/Fas ligand expression in neonates with pontosubicular neuron necrosis
    Van Landeghem, FKH
    Felderhoff-Mueser, U
    Moysich, A
    Stadelmann, C
    Obladen, M
    Brück, W
    Bührer, C
    PEDIATRIC RESEARCH, 2002, 51 (02) : 129 - 135
  • [34] Fas (CD95) and Fas-ligand (CD95-L) expression in osteosarcoma (OS): Analysis of 93 cases.
    Reith, J
    Casanova, J
    Scarborough, M
    LABORATORY INVESTIGATION, 2001, 81 (01) : 18A - 18A
  • [35] SERUM SOLUBLE FAS AND SOLUBLE FAS LIGAND IN HYPERTENSION IN PREGNANCY
    Karthikeyan, Vellore J.
    Jessani, Shahirose
    Balakrishnan, Balu
    Lane, Deirdre A.
    Baghdadi, Sabah
    Beevers, D. Gareth
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [36] Tumor cells in basal cell carcinoma (BCC) express fas ligand but not Fas antigen (CD95).
    GutierrezSteil, C
    WroneSmith, T
    Melton, J
    Swanson, J
    Nickoloff, BJ
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (04) : 191 - 191
  • [37] Selective involvement of the Fas (CD95)/Fas ligand pathway in bone marrow B cell progenitors
    Laouar, Y
    Vasseur, F
    Moreau, G
    Garcia, C
    Pasqualetto, V
    Waché, AC
    Ezine, S
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (05) : 1402 - 1409
  • [38] Blood-soluble Fas/APO-1 (CD95) in chronic lymphocytic leukemia
    Vilpo, J
    Vilpo, L
    Seishima, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 62 (05) : 352 - 353
  • [39] Fas (CD95) and Fas-ligand (CD95-L) expression in osteosarcoma (OS): Analysis of 93 cases.
    Reith, J
    Casanova, J
    Scarborough, M
    MODERN PATHOLOGY, 2001, 14 (01) : 18A - 18A
  • [40] Elevation of soluble Fas (APO-1, CD95) ligand in natural aging and Werner syndrome
    Goto, Makoto
    BIOSCIENCE TRENDS, 2008, 2 (03) : 124 - 127